EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patent foramen ovale closure versus drug therapy in patients over 60 years and a follow‐up of 5 years

Angelika Eichelmann, Ralf Kubini, Dejan Nachoski, Christoph Kosinski, Michael Becker, Ali Aljalloud

Clinical Cardiology · 2024

DOI: 10.1002/clc.24251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Angelika Eichelmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Bethlehem Hospital Stolberg, Stolberg, Germany. Hauptthemen laut MEDLINE: Foramen Ovale, Patent, Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The advantages of patent foramen ovale (PFO) closure as protection from a recurrence of stroke remains controversial compared to drug therapy, especially in patients over 60 years. Hypothesis The aim of the study is to compare recurrence of stroke in patients over 60 years old with PFO closure versus drug therapy alone.

Methods

We included 342 patients over 60 years who suffered a crytopgenic stroke, and were also accepted for a PFO closure. 199 patients refused a PFO closure and were treated with medical therapy alone, whereas 143 patients underwent a PFO closure procedure.

Results

The mean follow up time was 5.5 ± 1.5 years. All patients in Group B showed persistent shunt in the follow‐up period ( n = 199, 100%). In Group A, seven patients were diagnosed with residual shunt during echocardiography examination (5%). A new onset of atrial fibrillation occurred in seven patients in Group A (5%) and six patients in Group B (3%), p = .117. Recurrent stroke occurred in 3 patients in Group A (2%) and 11 patients in Group B (6%), p = .021. One patient died of unknown reason (1%) and two patients were lost due to neurological death (1%) in Group B, whereas no patients in Group A died during the follow‐up period.

Conclusion

Our results show that strict exclusion of patients over 60 years from PFO closure should be reconsidered. As life expectancies are increasing, patients should be considered for same treatment as younger patients, since the outcomes are improved compared to patients treated with medical therapy alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Foramen Ovale, PatentAtrial FibrillationStrokeHumansMiddle AgedFollow-Up StudiesCerebral Infarction

Stichwörter der Autor:innen

PFO and atrial fibrillationPFO closurecryptogenic strokeelder patientspatent foramen ovale

Autor:innen und Institutionen

  • Department of Pediatrics, Bethlehem Hospital Stolberg, Stolberg, Germany.
  • Rhein-Maas Hospital, Department of Cardiology, Nephrology and Internal Intensive Care, Würselen, Germany.
  • Department of Neurology, Rhein-Maas Hospital, Würselen, Germany.
  • Department of Cardiac Surgery, RWTH University Hospital Aachen, Aachen, Germany.

Zitieren

APA

Eichelmann, A., Kubini, R., Nachoski, D., Kosinski, C., Becker, M., & Aljalloud, A. (2024). Patent foramen ovale closure versus drug therapy in patients over 60 years and a follow‐up of 5 years. Clinical Cardiology. https://doi.org/10.1002/clc.24251

Vancouver

Eichelmann A, Kubini R, Nachoski D, Kosinski C, Becker M, Aljalloud A. Patent foramen ovale closure versus drug therapy in patients over 60 years and a follow‐up of 5 years. Clinical Cardiology. 2024. doi:10.1002/clc.24251

BibTeX
@article{Eichelmann2024,
  author = {Eichelmann, Angelika and Kubini, Ralf and Nachoski, Dejan and Kosinski, Christoph and Becker, Michael and Aljalloud, Ali},
  title = {Patent foramen ovale closure versus drug therapy in patients over 60 years and a follow‐up of 5 years},
  journal = {Clinical Cardiology},
  year = {2024},
  doi = {10.1002/clc.24251}
}
Kostenlos starten →